PMID- 30483258
OWN - NLM
STAT- MEDLINE
DCOM- 20191003
LR  - 20191007
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 9
DP  - 2018
TI  - Contribution of Dendritic Cell Responses to Sepsis-Induced Immunosuppression and 
      to Susceptibility to Secondary Pneumonia.
PG  - 2590
LID - 10.3389/fimmu.2018.02590 [doi]
LID - 2590
AB  - Dendritic cells (DCs) are bone marrow derived cells which continuously seed in 
      peripheral tissue. During infection, DCs play an essential interface between 
      innate and adaptive immunity. Pneumonia is a lung inflammation triggered by 
      pathogens and is characterized by excessive release of inflammatory cytokines 
      that activate innate and acquired immunity. Pneumonia induces a rapid and 
      protracted state of susceptibility to secondary infection, a state so-called 
      sepsis-induced immunosuppression. In this review, we focus on the role of DCs in 
      the development of this state of immunosuppression. Early during inflammation, 
      activated DCs are characterized by decreased capacity of antigen (cross)- 
      presentation of newly encountered antigens and decreased production of 
      immunogenic cytokines, and sepsis-induced immunosuppression is mainly explained 
      by a depletion of immature DCs which had all become mature. At a later stage, 
      newly formed respiratory immature DCs are locally programmed by an immunological 
      scare left-over by inflammation to induce tolerance. Tolerogenic Blimp1+ DCs 
      produce suppressive cytokines such as tumor growth factor-B and participate to 
      the maintenance of a local tolerogenic environment notably characterized by 
      accumulation of Treg cells. In mice, the restoration of the immunogenic functions 
      of DCs restores the mucosal immune response to pathogens. In humans, the 
      modulation of inflammation by glucocorticoid during sepsis or trauma preserves DC 
      immunogenic functions and is associated with resistance to secondary pneumonia. 
      Finally, we propose that the alterations of DCs during and after inflammation can 
      be used as biomarkers of susceptibility to secondary pneumonia and are promising 
      therapeutic targets to enhance outcomes of patients with secondary pneumonia.
FAU - Bouras, Marwan
AU  - Bouras M
AD  - Surgical Intensive Care Unit, Hotel Dieu, University Hospital of Nantes, Nantes, 
      France.
AD  - EA3826 Therapeutiques Anti-Infectieuses, Institut de Recherche en Sante 2 Nantes 
      Biotech, Medical University of Nantes, Nantes, France.
FAU - Asehnoune, Karim
AU  - Asehnoune K
AD  - Surgical Intensive Care Unit, Hotel Dieu, University Hospital of Nantes, Nantes, 
      France.
AD  - EA3826 Therapeutiques Anti-Infectieuses, Institut de Recherche en Sante 2 Nantes 
      Biotech, Medical University of Nantes, Nantes, France.
FAU - Roquilly, Antoine
AU  - Roquilly A
AD  - Surgical Intensive Care Unit, Hotel Dieu, University Hospital of Nantes, Nantes, 
      France.
AD  - EA3826 Therapeutiques Anti-Infectieuses, Institut de Recherche en Sante 2 Nantes 
      Biotech, Medical University of Nantes, Nantes, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20181113
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Cytokines)
SB  - IM
MH  - Animals
MH  - Cytokines/immunology
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Immune Tolerance/*immunology
MH  - Inflammation/immunology
MH  - Pneumonia/*immunology
MH  - Sepsis/*immunology
MH  - T-Lymphocytes, Regulatory/immunology
PMC - PMC6243084
OTO - NOTNLM
OT  - dendritic cells
OT  - immunity
OT  - inflammation
OT  - innate
OT  - intensive care units
OT  - mucosal immunity
OT  - pneumonia
OT  - steroids
EDAT- 2018/11/30 06:00
MHDA- 2019/10/08 06:00
PMCR- 2018/01/01
CRDT- 2018/11/29 06:00
PHST- 2018/06/29 00:00 [received]
PHST- 2018/10/22 00:00 [accepted]
PHST- 2018/11/29 06:00 [entrez]
PHST- 2018/11/30 06:00 [pubmed]
PHST- 2019/10/08 06:00 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2018.02590 [doi]
PST - epublish
SO  - Front Immunol. 2018 Nov 13;9:2590. doi: 10.3389/fimmu.2018.02590. eCollection 
      2018.